While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

In a small Phase II trial in China, the drug triggered an average 15.1% weight loss over 12 weeks. Novo Nordisk now hopes to conduct a global Phase I/II trial to fast-track the drug to the global ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight loss drug trial.

Novo Nordisk has trailing 12-months revenues of $40.411 billion, and I forecast that this will increase at an 18% CAGR over the next two years. The result of my forecast is $56.27 billion.

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with ... Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks.

For more than a year, Novo Nordisk’s market value surpassed Denmark’s entire gross domestic product. But investors have soured on the company as it has faced increasingly fierce competition.